Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 18.65% is 526% above its 5-year average of -4.38%, near the high end of its 5-year range (-98.39%–34.34%).
138.03% above its 12-month average of 7.83%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 6.83%.
RETURN ON ASSETS (ROA)
18.65%
RETURN ON ASSETS (ROA) AVG TTM
7.83%
RETURN ON ASSETS (ROA) AVG 3Y
-23.56%
RETURN ON ASSETS (ROA) AVG 5Y
-4.38%
RETURN ON ASSETS (ROA) AVG 10Y
-188.83%
RETURN ON ASSETS (ROA) AVG 15Y
-31.84%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+138.03%
CURRENT VS 3Y AVG
+179.18%
CURRENT VS 5Y AVG
+525.80%
CURRENT VS 10Y AVG
+109.88%
CURRENT VS 15Y AVG
+158.57%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.94%
median of 845 covered companies
CURRENT VS SECTOR MEDIAN
+158.39%
vs the sector median at left
Nutex Health, Inc.
Market Cap
$1.53B
Return on Assets (ROA)
18.65%
TTM Avg
7.83%
3Y Avg
-23.56%
5Y Avg
-4.38%
Market Cap
$1.54B
Return on Assets (ROA)
-25.60%
TTM Avg
-33.58%
3Y Avg
-30.56%
5Y Avg
-19.71%
Market Cap
$1.54B
Return on Assets (ROA)
-52.77%
TTM Avg
-17.21%
3Y Avg
-29.94%
5Y Avg
-28.87%
Market Cap
$1.54B
Return on Assets (ROA)
-31.37%
TTM Avg
-48.93%
3Y Avg
-40.51%
5Y Avg
-30.14%
Market Cap
$1.54B
Return on Assets (ROA)
20.98%
TTM Avg
9.19%
3Y Avg
12.55%
5Y Avg
16.89%
Market Cap
$1.49B
Return on Assets (ROA)
10.96%
TTM Avg
-5.00%
3Y Avg
-12.25%
5Y Avg
-27.07%
Market Cap
$1.49B
Return on Assets (ROA)
6.64%
TTM Avg
5.09%
3Y Avg
3.45%
5Y Avg
4.26%
Market Cap
$1.46B
Return on Assets (ROA)
-16.72%
TTM Avg
-18.71%
3Y Avg
-15.50%
5Y Avg
-12.14%
Market Cap
$1.46B
Return on Assets (ROA)
-29.88%
TTM Avg
-23.31%
3Y Avg
-25.68%
5Y Avg
-25.68%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nutex Health, Inc. (NUTX) | $1.53B | 18.65% | 7.83% | -23.56% | -4.38% |
| uniQure N.V. (QURE)vs › | $1.54B | -25.60% | -33.58% | -30.56% | -19.71% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.54B | -52.77% | -17.21% | -29.94% | -28.87% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -31.37% | -48.93% | -40.51% | -30.14% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 20.98% | 9.19% | 12.55% | 16.89% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 10.96% | -5.00% | -12.25% | -27.07% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.49B | 6.64% | 5.09% | 3.45% | 4.26% |
| GH Research PLC (GHRS)vs › | $1.46B | -16.72% | -18.71% | -15.50% | -12.14% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.46B | -29.88% | -23.31% | -25.68% | -25.68% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.60B | -43.15% | -37.60% | -124.49% | -99.59% |
ROA
18.6%
ROE
45.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 7.71% |
| 2024-12-31 | 7.96% |
| 2023-12-31 | -11.50% |
| 2022-12-31 | -98.39% |
| 2021-12-31 | 33.60% |
| 2020-12-31 | 34.34% |
| 2019-12-31 | 11.67% |
| 2018-12-31 | -626.18% |
| 2017-12-31 | 17.49% |
| 2016-12-31 | -1454.92% |
| 2015-12-31 | 1.10% |
| 2014-12-31 | -243.72% |
| 2013-12-31 | 23.38% |
| 2012-12-31 | -217.70% |
| 2011-12-31 | -18.50% |
| 2010-12-31 | 6.77% |
| 2009-12-31 | 34.25% |
| 2008-12-31 | 27.82% |
